Dr. Kerry Culm is Head of Translational Medicine and Early Development at ModeX, responsible for the clinical development of novel multispecific therapeutics for immuno-oncology and infectious disease indications. Kerry brings 20 years of clinical drug development expertise and experience in small molecule and therapeutic protein development to the company. She has a demonstrated record of leadership in guiding multiple projects into and through clinical development, and in creating strong collaborative teams that delivered multiple innovative medicines with high quality and accelerated speed. Prior to joining ModeX, she was Vice President of Clinical Development at OncXerna Therapeutics Inc., where she worked to deliver next-generation precision medicines by leveraging a biomarker platform that prospectively identified cancer patients for targeted therapies. Previously, Kerry was the Head of Clinical Pharmacology and Quantitative Bioanalytics at ImmunoGen Inc., where she and her team advanced transformative antibody-drug conjugates in both solid tumor and hematological cancer indications. Kerry spent 13 years at Sanofi Genzyme, most recently serving as a Global Project Head, where she led therapeutic project teams for Fabry disease, Gaucher disease type 3 and multiple gangliosidosis/galatosialidosis indications.
Kerry received a B.S. in biochemical pharmacology from the State University of New York at Buffalo. She received a Ph.D. in pharmacology and experimental therapeutics at Tufts University School of Medicine.